Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 380 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Hable con su médico sobre las opciones de cirugía de mama February 13, 2024 FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma February 28, 2024 FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... November 30, 2023 Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of... January 15, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed...
